http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#Head http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#assertion http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#provenance http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#pubinfo http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#assertion http://purl.obolibrary.org/obo/DOID_3908 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3908 http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00317 http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association http://www.w3.org/2000/01/rdf-schema#label iressa is indicated for the first line treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test see clinical studies 14 limitation of use safety and efficacy of iressa have not been established in patients with metastatic nsclc whose tumors have egfr mutations other than exon 19 deletions or exon 21 l858r substitution mutations see clinical studies 14 iressa is a tyrosine kinase inhibitor indicated for the first line treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test 1 limitation of use safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 l858r substitution mutations 1 http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00317 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#provenance http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#pubinfo http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#sig http://purl.org/nanopub/x/hasSignature RNrbiTAZ0oTLMa2F+6RaQePJhdUK9E11i5mB7Wi5X6pvI0ZHQpyfNXWPniDRdraBK17/6qWOhRNw5DFonBwoBvrbXehjhgpWVPZEmZfx30InQ/NFCoNvykdE/ub+1c299DOwnHCTw+ac5Ig72e/qK6Wxp5v1QHnVh1I5VHiilWU= http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c http://purl.org/dc/terms/created 2021-06-14T09:10:10.059+02:00 http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs